Abstract
HIV-infected individuals have excess rates of invasive pneumococcal disease. We investigated risk factors for nasopharyngeal pneumococcal colonization at baseline and after 9 months in 96 HIV patients immunized twice with 7- valent pneumococcal conjugate vaccine ±1mg CPG 7909. In total, 22 patients (23%) were colonized, 11 at baseline only, four at both baseline and 9 months, and seven at 9 months only. Compared to non-colonized patients, more colonized patients were smokers, had lower CD4+ nadir and had an AIDS-diagnosis. Immunization, antiretroviral treatment and the CPG adjuvant had no impact on colonization. These results suggest preventive strategies in addition to pneumococcal immunization.
MeSH terms
-
AIDS-Related Opportunistic Infections / immunology
-
AIDS-Related Opportunistic Infections / microbiology
-
AIDS-Related Opportunistic Infections / prevention & control*
-
CD4-Positive T-Lymphocytes
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Cohort Studies
-
Colony Count, Microbial
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Nasopharynx / microbiology*
-
Pneumococcal Infections / immunology
-
Pneumococcal Infections / microbiology
-
Pneumococcal Infections / prevention & control*
-
Pneumococcal Vaccines / immunology*
-
Randomized Controlled Trials as Topic
-
Risk Factors
-
Smoking / adverse effects
-
Smoking / immunology*
-
Streptococcus pneumoniae / growth & development
-
Streptococcus pneumoniae / immunology*
-
Vaccines, Conjugate / immunology*
Substances
-
Pneumococcal Vaccines
-
Vaccines, Conjugate